Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.91
NAS:LGND's Cash-to-Debt is ranked lower than
83% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. NAS:LGND: 0.91 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:LGND' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.14  Med: 0.52 Max: No Debt
Current: 0.91
Equity-to-Asset 0.61
NAS:LGND's Equity-to-Asset is ranked lower than
57% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:LGND: 0.61 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:LGND' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.83  Med: 0.15 Max: 0.83
Current: 0.61
-0.83
0.83
Debt-to-Equity 0.55
NAS:LGND's Debt-to-Equity is ranked lower than
70% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. NAS:LGND: 0.55 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:LGND' s Debt-to-Equity Range Over the Past 10 Years
Min: -9.6  Med: 0.53 Max: 28.74
Current: 0.55
-9.6
28.74
Debt-to-EBITDA 3.15
NAS:LGND's Debt-to-EBITDA is ranked lower than
69% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. NAS:LGND: 3.15 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NAS:LGND' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -20.3  Med: 0.85 Max: 12.77
Current: 3.15
-20.3
12.77
Interest Coverage 5.08
NAS:LGND's Interest Coverage is ranked lower than
92% of the 496 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:LGND: 5.08 )
Ranked among companies with meaningful Interest Coverage only.
NAS:LGND' s Interest Coverage Range Over the Past 10 Years
Min: 0.06  Med: 3.82 Max: No Debt
Current: 5.08
Piotroski F-Score: 7
Altman Z-Score: 6.43
Beneish M-Score: -2.11
WACC vs ROIC
7.77%
4.96%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 45.86
NAS:LGND's Operating Margin % is ranked higher than
96% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. NAS:LGND: 45.86 )
Ranked among companies with meaningful Operating Margin % only.
NAS:LGND' s Operating Margin % Range Over the Past 10 Years
Min: -466.69  Med: -6.83 Max: 45.86
Current: 45.86
-466.69
45.86
Net Margin % 12.76
NAS:LGND's Net Margin % is ranked higher than
80% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. NAS:LGND: 12.76 )
Ranked among companies with meaningful Net Margin % only.
NAS:LGND' s Net Margin % Range Over the Past 10 Years
Min: -359.19  Med: 8.57 Max: 2184.64
Current: 12.76
-359.19
2184.64
ROE % 4.47
NAS:LGND's ROE % is ranked higher than
79% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. NAS:LGND: 4.47 )
Ranked among companies with meaningful ROE % only.
NAS:LGND' s ROE % Range Over the Past 10 Years
Min: -1046.55  Med: 30.84 Max: 997.71
Current: 4.47
-1046.55
997.71
ROA % 2.62
NAS:LGND's ROA % is ranked higher than
80% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. NAS:LGND: 2.62 )
Ranked among companies with meaningful ROA % only.
NAS:LGND' s ROA % Range Over the Past 10 Years
Min: -56.92  Med: 3.17 Max: 112.83
Current: 2.62
-56.92
112.83
ROC (Joel Greenblatt) % 562.38
NAS:LGND's ROC (Joel Greenblatt) % is ranked higher than
98% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. NAS:LGND: 562.38 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:LGND' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1252.88  Med: -29.29 Max: 6370.4
Current: 562.38
-1252.88
6370.4
3-Year Revenue Growth Rate 30.40
NAS:LGND's 3-Year Revenue Growth Rate is ranked higher than
80% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NAS:LGND: 30.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:LGND' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -65  Med: 8.05 Max: 91
Current: 30.4
-65
91
3-Year EBITDA Growth Rate 46.10
NAS:LGND's 3-Year EBITDA Growth Rate is ranked higher than
86% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. NAS:LGND: 46.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:LGND' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -76.7  Med: -10.3 Max: 112.5
Current: 46.1
-76.7
112.5
GuruFocus has detected 3 Warning Signs with Ligand Pharmaceuticals Inc NAS:LGND.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:LGND's 30-Y Financials

Financials (Next Earnings Date: 2018-02-23)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

LGND Guru Trades in Q4 2016

Paul Tudor Jones Sold Out
Ken Fisher 65,490 sh (-9.53%)
Joel Greenblatt 33,965 sh (-11.16%)
Columbia Wanger 88,597 sh (-28.32%)
» More
Q1 2017

LGND Guru Trades in Q1 2017

Mario Gabelli 5,000 sh (New)
Jim Simons 101,115 sh (New)
Joel Greenblatt 117,749 sh (+246.68%)
Columbia Wanger 94,431 sh (+6.58%)
Ken Fisher 60,390 sh (-7.79%)
» More
Q2 2017

LGND Guru Trades in Q2 2017

Eaton Vance Worldwide Health Sciences Fund 55,407 sh (New)
Columbia Wanger 291,037 sh (+208.20%)
Mario Gabelli 5,000 sh (unchged)
Joel Greenblatt Sold Out
Ken Fisher 60,300 sh (-0.15%)
Jim Simons 78,094 sh (-22.77%)
» More
Q3 2017

LGND Guru Trades in Q3 2017

Chuck Royce 62 sh (New)
Columbia Wanger 334,919 sh (+15.08%)
Mario Gabelli 5,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 55,407 sh (unchged)
Jim Simons Sold Out
Ken Fisher 56,355 sh (-6.54%)
» More
» Details

Insider Trades

Latest Guru Trades with LGND

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2017-09-30 Reduce -6.54%$116.75 - $137.94 $ 129.862%56,355
Ken Fisher 2017-06-30 Reduce -0.15%$104.13 - $123.87 $ 129.8616%60,300
Joel Greenblatt 2017-06-30 Sold Out 0.16%$104.13 - $123.87 $ 129.8616%0
Joel Greenblatt 2017-03-31 Add 246.68%0.11%$100.38 - $109.54 $ 129.8623%117,749
Ken Fisher 2017-03-31 Reduce -7.79%$100.38 - $109.54 $ 129.8623%60,390
Mario Gabelli 2017-03-31 New Buy$100.38 - $109.54 $ 129.8623%5,000
Ken Fisher 2016-12-31 Reduce -9.53%$91.16 - $109.45 $ 129.8628%65,490
Joel Greenblatt 2016-12-31 Reduce -11.16%0.01%$91.16 - $109.45 $ 129.8628%33,965
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:SRPT, NAS:ONCE, NAS:AGIO, SZSE:002603, SHSE:603233, NAS:AAAP, NAS:PTLA, NAS:BGNE, BOM:532523, SZSE:002287, NAS:AVXS, NAS:BPMC, SZSE:000990, XKRX:215600, LSE:ABC, NAS:LOXO, SHSE:600161, XTER:MOR, XSWX:BION, HKSE:00570 » details
Traded in other countries:LGDN.Germany,
Headquarter Location:USA
Ligand Pharmaceuticals Inc is a biopharmaceutical company. Its business model is based upon the concept of acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure.

Ligand Pharmaceuticals is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

Ratios

vs
industry
vs
history
PE Ratio 188.20
LGND's PE Ratio is ranked lower than
98% of the 247 Companies
in the Global Biotechnology industry.

( Industry Median: 29.02 vs. LGND: 188.20 )
Ranked among companies with meaningful PE Ratio only.
LGND' s PE Ratio Range Over the Past 10 Years
Min: 0.95  Med: 95.95 Max: 385.93
Current: 188.2
0.95
385.93
Forward PE Ratio 34.84
LGND's Forward PE Ratio is ranked lower than
76% of the 68 Companies
in the Global Biotechnology industry.

( Industry Median: 24.21 vs. LGND: 34.84 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 188.20
LGND's PE Ratio without NRI is ranked lower than
98% of the 245 Companies
in the Global Biotechnology industry.

( Industry Median: 29.70 vs. LGND: 188.20 )
Ranked among companies with meaningful PE Ratio without NRI only.
LGND' s PE Ratio without NRI Range Over the Past 10 Years
Min: 8.05  Med: 128.79 Max: 99999999.99
Current: 188.2
8.05
99999999.99
Price-to-Owner-Earnings 102.39
LGND's Price-to-Owner-Earnings is ranked lower than
89% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 38.46 vs. LGND: 102.39 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
LGND' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 1.5  Med: 121.3 Max: 1586.82
Current: 102.39
1.5
1586.82
PB Ratio 6.78
LGND's PB Ratio is ranked lower than
73% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. LGND: 6.78 )
Ranked among companies with meaningful PB Ratio only.
LGND' s PB Ratio Range Over the Past 10 Years
Min: 5.26  Med: 19.16 Max: 174.72
Current: 6.78
5.26
174.72
PS Ratio 22.68
LGND's PS Ratio is ranked lower than
67% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. LGND: 22.68 )
Ranked among companies with meaningful PS Ratio only.
LGND' s PS Ratio Range Over the Past 10 Years
Min: 4.63  Med: 19.2 Max: 714.32
Current: 22.68
4.63
714.32
Price-to-Free-Cash-Flow 35.42
LGND's Price-to-Free-Cash-Flow is ranked lower than
56% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 36.07 vs. LGND: 35.42 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
LGND' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 34.17  Med: 65.36 Max: 305.2
Current: 35.42
34.17
305.2
Price-to-Operating-Cash-Flow 35.31
LGND's Price-to-Operating-Cash-Flow is ranked lower than
68% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 25.45 vs. LGND: 35.31 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
LGND' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 30.86  Med: 57.1 Max: 3653.33
Current: 35.31
30.86
3653.33
EV-to-EBIT 46.71
LGND's EV-to-EBIT is ranked lower than
84% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. LGND: 46.71 )
Ranked among companies with meaningful EV-to-EBIT only.
LGND' s EV-to-EBIT Range Over the Past 10 Years
Min: -933.3  Med: -3.2 Max: 553.2
Current: 46.71
-933.3
553.2
EV-to-EBITDA 39.19
LGND's EV-to-EBITDA is ranked lower than
81% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. LGND: 39.19 )
Ranked among companies with meaningful EV-to-EBITDA only.
LGND' s EV-to-EBITDA Range Over the Past 10 Years
Min: -227.8  Med: 42.1 Max: 823.2
Current: 39.19
-227.8
823.2
EV-to-Revenue 21.41
LGND's EV-to-Revenue is ranked lower than
63% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. LGND: 21.41 )
Ranked among companies with meaningful EV-to-Revenue only.
LGND' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.9  Med: 18.2 Max: 573.7
Current: 21.41
2.9
573.7
Shiller PE Ratio 207.70
LGND's Shiller PE Ratio is ranked lower than
90% of the 70 Companies
in the Global Biotechnology industry.

( Industry Median: 41.36 vs. LGND: 207.70 )
Ranked among companies with meaningful Shiller PE Ratio only.
LGND' s Shiller PE Ratio Range Over the Past 10 Years
Min: 23.68  Med: 75.53 Max: 384.6
Current: 207.7
23.68
384.6
Current Ratio 0.97
LGND's Current Ratio is ranked lower than
90% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. LGND: 0.97 )
Ranked among companies with meaningful Current Ratio only.
LGND' s Current Ratio Range Over the Past 10 Years
Min: 0.28  Med: 1.72 Max: 12.94
Current: 0.97
0.28
12.94
Quick Ratio 0.95
LGND's Quick Ratio is ranked lower than
87% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. LGND: 0.95 )
Ranked among companies with meaningful Quick Ratio only.
LGND' s Quick Ratio Range Over the Past 10 Years
Min: 0.26  Med: 1.61 Max: 12.87
Current: 0.95
0.26
12.87
Days Inventory 284.07
LGND's Days Inventory is ranked lower than
86% of the 473 Companies
in the Global Biotechnology industry.

( Industry Median: 134.39 vs. LGND: 284.07 )
Ranked among companies with meaningful Days Inventory only.
LGND' s Days Inventory Range Over the Past 10 Years
Min: 33.18  Med: 79.07 Max: 284.07
Current: 284.07
33.18
284.07
Days Sales Outstanding 36.31
LGND's Days Sales Outstanding is ranked higher than
70% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. LGND: 36.31 )
Ranked among companies with meaningful Days Sales Outstanding only.
LGND' s Days Sales Outstanding Range Over the Past 10 Years
Min: 5.79  Med: 49.24 Max: 146.43
Current: 36.31
5.79
146.43
Days Payable 202.30
LGND's Days Payable is ranked higher than
74% of the 434 Companies
in the Global Biotechnology industry.

( Industry Median: 57.10 vs. LGND: 202.30 )
Ranked among companies with meaningful Days Payable only.
LGND' s Days Payable Range Over the Past 10 Years
Min: 179.13  Med: 282.1 Max: 822.72
Current: 202.3
179.13
822.72

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.70
LGND's 3-Year Average Share Buyback Ratio is ranked higher than
91% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. LGND: -0.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
LGND' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -36.5  Med: -8.15 Max: 2.1
Current: -0.7
-36.5
2.1

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 24.74
LGND's Price-to-Tangible-Book is ranked lower than
93% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. LGND: 24.74 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
LGND' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.83  Med: 19.88 Max: 206.67
Current: 24.74
4.83
206.67
Price-to-Intrinsic-Value-Projected-FCF 3.89
LGND's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
59% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 3.43 vs. LGND: 3.89 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
LGND' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 3.78  Med: 4.81 Max: 40.37
Current: 3.89
3.78
40.37
Price-to-Median-PS-Value 1.18
LGND's Price-to-Median-PS-Value is ranked lower than
71% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. LGND: 1.18 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
LGND' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.19  Med: 0.62 Max: 33.23
Current: 1.18
0.19
33.23
Price-to-Peter-Lynch-Fair-Value 7.53
LGND's Price-to-Peter-Lynch-Fair-Value is ranked lower than
99.99% of the 65 Companies
in the Global Biotechnology industry.

( Industry Median: 1.79 vs. LGND: 7.53 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
LGND' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 7.37  Med: 8.2 Max: 8.58
Current: 7.53
7.37
8.58
Price-to-Graham-Number 14.38
LGND's Price-to-Graham-Number is ranked lower than
100% of the 185 Companies
in the Global Biotechnology industry.

( Industry Median: 2.69 vs. LGND: 14.38 )
Ranked among companies with meaningful Price-to-Graham-Number only.
LGND' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.65  Med: 4.08 Max: 33.79
Current: 14.38
1.65
33.79
Earnings Yield (Greenblatt) % 2.12
LGND's Earnings Yield (Greenblatt) % is ranked higher than
79% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. LGND: 2.12 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
LGND' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -59.1  Med: -0.7 Max: 2.18
Current: 2.12
-59.1
2.18
Forward Rate of Return (Yacktman) % 68.99
LGND's Forward Rate of Return (Yacktman) % is ranked lower than
99.99% of the 132 Companies
in the Global Biotechnology industry.

( Industry Median: 13.13 vs. LGND: 68.99 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
LGND' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -50.7  Med: -13.3 Max: 69.1
Current: 68.99
-50.7
69.1

More Statistics

Revenue (TTM) (Mil) $128.82
EPS (TTM) $ 0.69
Beta0.78
Short Percentage of Float20.06%
52-Week Range $95.08 - 149.31
Shares Outstanding (Mil)21.11

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 135 180 222 262
EPS ($) 2.60 3.23 4.31 5.25
EPS without NRI ($) 2.60 3.23 4.31 5.25
EPS Growth Rate
(Future 3Y To 5Y Estimate)
25.00%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}